



Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,
Worli, Mumbai - 400 030. India
Tel. : + 91 22 6663 5456
Fax : +91 22 6663 5460
E-mail : auro@aurolabs.com
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :
K-56, M. I. D. C. Tarapur,
Dist. Palghar, Maharashtra - 401506.
CIN No. L33125MH1989PLC051910

Date: October 22, 2019

To
BSE Limited,
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Reg: Security Code No. 530233:

Sub: Outcome of the Board Meeting dated October 22, 2019:

Dear Sir / Ma'am,

Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors at their Meeting held today (i.e. **Tuesday, October 22, 2019**), has approved the Unaudited Financial Results for the quarter & half year ended September 30, 2019 as recommended by the Audit Committee alongwith the Limited Review Report received from the Statutory Auditors.

In this regard, we are enclosing herewith:

- Unaudited Financial Results for the quarter & half year ended September 30, 2019.
- Limited Review Report received from the Statutory Auditor of the Company.
- Statement of Assets & Liabilities as on September 30, 2019.
- Cash Flow Statement for the half year ended September 30, 2019.

The Meeting of the Board commenced at 2.30 p.m. and concluded at 3.15 p.m. The results will be published in the newspaper pursuant to Regulation 47(1) (b) of SEBI (LODR) Regulations, 2015 in due course.

Kindly take the same on record and acknowledge.

Thanking You,

Yours Faithfully,
For AURO LABORATORIES LIMITED

Siddhartha Deorah

SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN: 00230796



Encl.: as above

AURO LABORATORIES LIMITED
CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR
BOISAR, DIST. PALGHAR 401506 , MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

ANNEXURE - I

PART - I							Rs. In Lakhs)
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2019							
Sr. No.	Particulars	3 Months ended	Preceding 3 Months ended	Corresponding 3 Months ended in the Previous Year	Half year Ended		Previous Year Ended
		30.09.2019 (Unaudited)	30.06.2019 (Unaudited)	30.09.2018 (Unaudited)	30.09.2019 (Unaudited)	30.09.2018 (Unaudited)	31.03.2019 (Audited)
1	Income from Operations						
	(a) Net Sales/Income from Operations (Net of excise duty)	1110.27	1,371.56	1254.91	2,481.83	2,301.69	4,682.31
2	Other Income	22.41	25.90	26.11	48.31	29.20	95.82
3	Total Revenue (1 + 2)	1,132.68	1,397.46	1,281.02	2,530.14	2,330.89	4,778.13
4	Expenses						
	a. Consumption of raw material	594.57	1,029.59	882.56	1,624.16	1,598.97	3,013.82
	b. Purchase of Stock-in-trade	1.65	24.10	-	25.75	1.04	24.91
	c. (Increase) / decrease in Finished Goods stock in trade and work in progress	(38.30)	(127.81)	(40.41)	(166.11)	(106.31)	(176.59)
	d. Employee benefits expense	103.3	102.65	91.43	205.95	178.08	407.07
	e. Finance Cost	11.45	15.52	18.84	26.97	41.64	72.22
	f. Depreciation and amortisation expenses	26.00	25.00	26.00	51.00	50.50	100.92
	g. Other Expenses	230.57	176.09	196.14	406.66	375.75	728.89
	Total Expenses (4)	929.24	1,245.14	1,174.56	2,174.38	2,139.67	4,171.24
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)	203.44	152.32	106.46	355.76	191.22	606.89
6	Exceptional items				-	-	
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)	203.44	152.32	106.46	355.76	191.22	606.89
8	Extraordinary items	-	-	-	-	-	
9	Profit / (Loss) before tax (7 ± 8)	203.44	152.32	106.46	355.76	191.22	606.89
10	Tax expense						
	(a) Current tax expenses for current year	58.92	41.89	26.62	100.81	47.80	161.69
	(b) MAT credit (where applicable)	-	-	-	-	-	
	(c) Defferered tax	-	-	-	-	-	5.25
11	Profit / (Loss) for the period from continuing operation (9± 10)	144.52	110.43	79.84	254.95	143.42	439.95
12	Profit / (Loss) for discontinuing operations	-	-	-	-	-	
13	Tax expense of discontinuing operations	-	-	-	-	-	
14	Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)	144.52	110.43	79.84	254.95	143.42	439.95
15	Other Comprehensive Income	(6.93)	10.68	17.16	3.75	17.16	8.11
16	Total Comprehensive Income for the period (14 ± 15)	137.59	121.11	97.00	258.70	160.58	448.06
17	Paid-up equity share capital (Face value of Rs. 10 each)	623.25	623.25	623.25	623.25	623.25	623.25
17	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	1,117.95
18	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):						
	(a) Basic	2.32	1.77	1.28	4.09	2.30	7.06
	(b) Diluted	2.32	1.77	1.28	4.09	2.30	7.06



Auro Laboratories Limited

Statement of Assets and Liabilities (Ind AS)

(Rs. In Lakh)

Particulars	As at 30.09.2019	As at 31.03.2019
	Unaudited	Audited
A ASSETS		
1. Non-Current Assets		
(a) Property, Plant and Equipment	1,420.98	1,458.62
(b) Capital Work -in-Progress	17.02	11.60
(c) Investment Property	-	-
(d) Financial Assets		
(i) Investments	4.88	4.88
(ii) Loans	-	-
(iii) Others	-	-
(e) Other non-current assets - Capital Advance	-	-
2. Current assets		
(c) Inventories	177.27	337.38
(b) Financial Assets		
(i) Investments	-	-
(ii) Trade Reveivables	688.48	850.38
(iii) Cash and cash equivalents	533.75	335.88
(iv) Bank balances other than (iii) above	64.01	74.88
(v) Loans	-	-
(vi) Others	210.59	272.92
(c) Other Current Assets	-	-
TOTAL ASSETS	3116.98	3346.54
B EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share Capital	623.25	623.25
(b) Other Equity	1,376.65	1,117.95
2. Liabilities		
(I) Non-Current Liabilities		
(a) Financial Liabilities		
(i) Other Financial Liabilities	221.27	614.93
(b) Provisions	161.53	194.50
(c) Deferred Tax Liabilities (Net)	149.67	149.67
(II) Current Liabilities		
(a) Financial Liabilities		
(i) Trade Payables	403.79	518.32
(b) Other Current Liabilities	79.15	78.10
(c) Provisions	65.86	49.82
(d) Current Tax Liabilities (net)	35.81	-
TOTAL EQUITY AND LIABILITIES	3116.98	3346.54

Notes:

- 1) The above unaudited financial results for the quarter ended 30th September, 2019 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 22nd October 2019.
- 2) Statement of Assets and Liabilities as on 30.09.2019.
- 3) Cash flow statement for the period ended 30.09.2019 in annexure 1
- 4) The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 5) Limited review has been carried out by the Statutory Auditors of the Company.

FOR & BEHALF OF BOARD OF DIRECTORS
AURO LABORATORIES LIMITED

SIDDHARHTA DEORAH
WHOLE TIME DIRECTOR
DIN NO. 00230796



Place : Mumbai
Date : 22.10.2019

Cash Flow Statement

Particulars	For the Half year ended 30.09.2019		For the Half year ended 30.09.2018	
	Amount	Amount	Amount	Amount
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		355.76		191.22
Add: Adjustments for:				
Depreciation and amortisation	51.00		50.50	
Other Non Cash Items	3.75		17.16	
Finance costs	26.97	81.72	41.64	109.30
		437.48		300.52
Less: Adjustment for:				
Interest income	2.35		4.66	
Dividend income	0.03	2.38	0.03	4.69
Operating profit / (loss) before working capital changes		435.10		295.83
Changes in working capital:				
Adjustments for (increase) / decrease in operating assets:				
Inventories	160.11		(136.32)	
Trade receivables	161.90		(264.57)	
Loans and advances	62.33		164.04	
Other Bank Balance	-			
Other non-current assets	-	384.34		(236.85)
		819.44		58.98
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	(114.53)		256.65	
Other current liabilities	1.05		(13.93)	
Other long-term liabilities				
Short-term provisions	16.04		(5.32)	
Long-term provisions				
		(97.44)		237.40
		722.00		296.38
Cash flow from extraordinary items		-		
Cash generated from operations		722.00		296.38
Net income tax (paid) / refunds		-		-
Net cash flow from / (used in) operating activities (A)		722.00		296.38
B. Cash flow from investing activities				
Capital expenditure on fixed assets, including capital advance				
Proceeds from sale of fixed assets	17.04		(143.75)	
Interest received				
- Others	2.35		4.66	
Dividend received				
- Others	0.03		0.03	
		19.42		(139.06)
Net income tax (paid) / refunds		(100.81)		(47.80)
Net cash flow from / (used in) investing activities (B)		(81.39)		(186.87)
C. Cash flow from financing activities				
Proceeds from long-term borrowings				
Repayment of borrowings & Net increase / (decrease) in working capital borrowings	(393.66)		2.49	
Proceeds from other short-term borrowings				
Repayment of other short-term borrowings	(32.97)		(83.25)	
Finance cost	(26.97)		(41.64)	
		(453.60)		(122.40)
Cash flow from extraordinary items				
Net cash flow from / (used in) financing activities (C)		(453.60)		(122.40)
Net increase/(decrease) in Cash & cash equivalents (A+B+C)		187.01		(12.89)
Cash and cash equivalents at the beginning of the year		410.75		225.03
Cash and cash equivalents at the end of the year		597.76		212.15





KHURDIA JAIN & CO.
CHARTERED ACCOUNTANTS

To,

The Board of Directors,
Auro Laboratories Limited.

We have reviewed the standalone Ind AS financial results of Auro Laboratories Ltd. ("the company") for the Quarter & half year ended September 30, 2019, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.


This Statement is the responsibility of the Company's Management and had been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements prepared in accordance with generally accepted accounting standards in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khurdia Jain & Co.
Chartered Accountants
Firm Reg. No. 120263W





Sampat Khurdia
Partner
Membership No. 033615
Place: Mumbai
Date: October 22, 2019.

UDIN: 19033615AAAEG8135